Development
Sanofi
SNY
$47.35
$0.2150.46%
NASDAQ
| 12/31/2023 | 06/30/2023 | 12/31/2022 | 09/30/2022 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | 1.24% | 2.84% | |
| Total Other Revenue | -- | -- | 49.92% | 38.92% | |
| Total Revenue | -- | -- | 2.99% | 4.10% | |
| Cost of Revenue | -- | -- | -0.71% | -0.11% | |
| Gross Profit | -- | -- | 4.68% | 6.04% | |
| SG&A Expenses | -- | -- | -2.22% | -0.19% | |
| Depreciation & Amortization | -- | -- | 15.26% | 16.62% | |
| Other Operating Expenses | -- | -- | -8.26% | 37.29% | |
| Total Operating Expenses | -- | -- | 0.26% | 2.99% | |
| Operating Income | -- | -- | 12.99% | 8.03% | |
| Income Before Tax | -- | -- | 18.68% | -9.49% | |
| Income Tax Expenses | -- | -- | 13.33% | -23.98% | |
| Earnings from Continuing Operations | -- | -- | 20.00% | -5.73% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -78.54% | -8.97% | |
| Net Income | -- | -- | 19.48% | -5.86% | |
| EBIT | -- | -- | 12.99% | 8.03% | |
| EBITDA | -- | -- | 7.51% | 3.13% | |
| EPS Basic | -- | -- | 19.52% | -5.80% | |
| Normalized Basic EPS | -- | -- | 4.12% | -8.38% | |
| EPS Diluted | -- | -- | 19.75% | -5.62% | |
| Normalized Diluted EPS | -- | -- | 4.64% | -7.94% | |
| Average Basic Shares Outstanding | -- | -- | -0.05% | -0.04% | |
| Average Diluted Shares Outstanding | -- | -- | -0.26% | -0.25% | |
| Dividend Per Share | -- | -- | -4.47% | -0.24% | |
| Payout Ratio | -- | -- | -- | -- | |